Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)

Core Insights - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is recognized as a leading gene therapy stock by hedge funds, with multiple analysts adjusting their price targets following the company's fiscal Q4 results [1][2][3] Financial Performance - Vertex reported a total revenue of $12.0 billion for the full year 2025, marking a 9% increase compared to the previous year [3] - The fiscal Q4 revenue reached $3.19 billion, reflecting a 10% growth year-over-year [3] Analyst Ratings and Price Targets - Canaccord raised its price target for Vertex to $441 from $411 while maintaining a Hold rating, noting a slight miss in Trikafta revenue against consensus [1] - Barclays adjusted its price target to $607 from $606 and kept an Overweight rating after the fiscal Q4 report [1] - H.C. Wainwright increased its price target to $591 from $518, reaffirming a Buy rating and highlighting the potential of povetacicept in primary membranous nephropathy [2] Product Pipeline - Vertex is a global biotechnology company focused on developing treatments for rare and serious diseases, with a diverse product pipeline addressing various disorders [4]